Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.51 |
| ▸ | FNTB | P49356 | 2/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34468351 | 0.84 | MAPT (0.51) | FNTAFNTBPGGT1BMAPTNPSR1 | |
| SCHEMBL34468432 | 0.82 | L3MBTL1 (0.53) | FNTAFNTBPGGT1BMAPTNPSR1 | |
| SCHEMBL29020717 | 0.81 | FNTA (0.52) | FNTAFNTBPGGT1BNPSR1NPC1 | |
| SCHEMBL30386308 | 0.81 | FNTA (0.52) | FNTAFNTBPGGT1BNPSR1NPC1 | |
| SCHEMBL34468431 | 0.81 | MAPT (0.50) | MAPTNPSR1NPC1ALDH1A1LMNA | |
| SCHEMBL34468403 | 0.79 | MAPT (0.48) | FNTAFNTBPGGT1BMAPTNPSR1 | |
| SCHEMBL12073842 | 0.78 | MAPT (0.56) | MAPTNPSR1NPC1ALDH1A1LMNA | |
| SCHEMBL20521279 | 0.78 | MAPT (0.58) | MAPTNPSR1NPC1ALDH1A1LMNA | |
| SCHEMBL34468349 | 0.78 | FNTA (0.51) | FNTAFNTBPGGT1BMAPTNPSR1 | |
| SCHEMBL31640194 | 0.78 | CHRM4 (0.50) | FNTAFNTBPGGT1BMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | FNTA 1794/4885FNTB 1160/4885PGGT1B 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.